The Clinical Utility of Y-PSMA2 Monoclonal Antibody in the Detection of Primary and Peripheral Blood Metastatic Prostate Cancer

Abstract

The monoclonal antibody 7E11-C5.3 was the first anti-PSMA antibody to be developed. It recognizes a PSMA intracellular epitope, is radio-labeled and used to detect early recurrent and metastatic prostate cancer. The monoclonal antibody Y-PSMA2 is a primary IgG2bκ mouse anti-human PSMA developed by Abazyme LCC (MA, USA). It recognizes an extracellular epitope on PSMA and is reactive with LNCap cell lines. The purpose of this study is to determine the utility of Y-PSMA2 monoclonal antibody for the detection of organ-confined (localized) prostate cancer, increased PSMA expression in poorly differentiated prostate tumors, and hematogenous prostate cancer cell dissemination.